Oral ulcer as an unusual feature of visceral leishmaniasis in an AIDS patient.

Department of Dermatology, Dr. Ram Manohar Lohia Hospital, New Delhi, India.
Indian Journal of Medical Sciences (Impact Factor: 1.67). 03/2007; 61(2):97-101. DOI: 10.4103/0019-5359.30350
Source: PubMed

ABSTRACT Leishmaniasis, a globally prevalent parasitic disease, occurs in three forms, viz, visceral, cutaneous and mucocutaneous. It is transmitted by female Phlebotomus sandflies. Human immunodeficiency virus (HIV) infection is increasing worldwide and several reports indicate a rising trend of VL / HIV co-infection, modifying the traditional anthroponotic pattern of VL transmission. India is one of the countries having the largest burden of leishmaniasis; nevertheless, there are very few HIV / leishmania co-infection cases reported so far. We report a 35-year-old homemaker infected with the human immunodeficiency virus; she presented with an oral ulcer. The investigations carried out on her revealed that she was afflicted by visceral leishmaniasis and the oral ulceration was a part of the same. This is only the second such case from the Indian subcontinent and more significantly from a non-endemic area.


Available from: Minakshi Bhardwaj, Jun 02, 2015
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: After HIV epidemic several countries reported co-infections of Leishmania with HIV. The co-infection of these two pathogens results into rapid disease progression, more severe disease and poor response to treatment. A systematic review of literature from India is presented here. On reviewing the literature since first case of visceral leishmaniasis (VL) and HIV was published from India in 1999, a number of cases of HIV-leishmania co-infections have been reported, but the proportion has been low (0.029-0.4%) as reported to other countries where both these diseases are co-endemic. So far, more than 89 cases of VL-HIV and 10 cases of cutaneous leishmaniasis (CL) with HIV have been published since 1999. Of these 10 cases, 5 had simple CL and 5 cases manifested with diffuse cutaneous leishmaniasis (DCL). In addition, one case of post-kala-azar mucocutaneous leishmaniasis (PKML) in a full blown AIDS patient has also been reported. In two cases no clear description could be ascertained whether these were cases of DCL or post-kala-azar dermal leishmaniasis (PKDL). Though the first case of VL-HIV co-infection was reported from sub-Himalayan state of Uttarakhand, most cases are reported from VL endemic state of Bihar. HIV-Leishmania is not alarmingly high in India. Most cases occurred during 1997-2007. After that the number of new cases has gone down. Most probably due to low HIV prevalence in VL and CL endemic regions and free supply of highly active anti-retroviral therapy (HAART) for HIV infected patients.
    International Journal of Infectious Diseases 10/2014; DOI:10.1016/j.ijid.2014.07.011 · 2.33 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Co-infection of leishmaniasis and HIV is increasingly reported. The clinical presentation of leishmaniasis is determined by the host immune response to the parasite; as a consequence, this presentation will be influenced by HIV-induced immunosuppression. As leishmaniasis commonly affects the skin, increasing immunosuppression changes the clinical presentation, such as in post-kala-azar dermal leishmaniasis (PKDL) and cutaneous leishmaniasis (CL); dermal lesions are also commonly reported in visceral leishmaniasis (VL) and HIV co-infection. We reviewed the literature with regard to dermal manifestations in leishmaniasis and HIV co-infection, in three clinical syndromes, according to the primary presentation: PKDL, VL, or CL. A wide variety of descriptions of dermal leishmaniasis in HIV co-infection has been reported. Lesions are commonly described as florid, symmetrical, non-ulcerating, nodular lesions with atypical distribution and numerous parasites. Pre-existing, unrelated dermal lesions may become parasitized. Parasites lose their tropism and no longer exclusively cause VL or CL. PKDL in HIV co-infected patients is more common and more severe and is not restricted to Leishmania donovani. In VL, dermal lesions occur in up to 18% of patients and may present as (severe) localized cutaneous leishmaniasis, disseminated cutaneous leishmaniasis (DL) or diffuse cutaneous leishmaniasis (DCL); there may be an overlap with para-kala-azar dermal leishmaniasis. In CL, dissemination in the skin may occur resembling DL or DCL; subsequent spread to the viscera may follow. Mucosal lesions are commonly found in VL or CL and HIV co-infection. Classical mucocutaneous leishmaniasis is more severe. Immune reconstitution disease (IRD) is uncommon in HIV co-infected patients with leishmaniasis on antiretroviral treatment (ART). With increasing immunosuppression, the clinical syndromes of CL, VL, and PKDL become more severe and may overlap. These syndromes may be best described as VL with disseminated cutaneous lesions (before, during, or after VL) and disseminated cutaneous leishmaniasis with or without visceralization.
    PLoS Neglected Tropical Diseases 11/2014; 8(11):e3258. DOI:10.1371/journal.pntd.0003258 · 4.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In regions where it is endemic, visceral leishmaniasis is an important opportunistic infectious disease in people living with HIV. Typically, clinical presentation of visceral leishmaniasis includes chronic fever, hepatosplenomegaly, and weight loss. In Leishmania infantum endemic regions in Europe, atypical visceral leishmaniasis presentations have been well documented, with almost every possible organ involved. However, such reports are rare in Leishmania donovani endemic regions such as east Africa. In this Personal View, we describe the various atypical disease presentations in patients screened as part of an HIV and visceral leishmaniasis clinical trial in north Ethiopia, where up to 40% of patients with visceral leishmaniasis are co-infected with HIV. Atypical presentations such as these are not covered in clinical guidelines used in these settings. Apart from the lack of diagnostic facilities, this gap contributes to the underdiagnosis of atypical visceral leishmaniasis, with associated morbidity and mortality. Involvement of clinicians experienced with the management of HIV and visceral leishmaniasis co-infection in the development of HIV clinical guidelines in affected regions is warranted.
    The Lancet Infectious Diseases 10/2014; 15(1). DOI:10.1016/S1473-3099(14)70833-3 · 19.45 Impact Factor